211 related articles for article (PubMed ID: 12036394)
1. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients.
Jones TE; Morris RG
Clin Pharmacokinet; 2002; 41(5):381-8. PubMed ID: 12036394
[TBL] [Abstract][Full Text] [Related]
2. Diltiazem-cyclosporin pharmacokinetic interaction--dose-response relationship.
Jones TE; Morris RG; Mathew TH
Br J Clin Pharmacol; 1997 Nov; 44(5):499-504. PubMed ID: 9384468
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients.
Chen YH; Zheng KL; Chen LZ; Dai YP; Fei JG; Qiu J; Li J
Transplant Proc; 2005 Dec; 37(10):4246-50. PubMed ID: 16387090
[TBL] [Abstract][Full Text] [Related]
5. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
[TBL] [Abstract][Full Text] [Related]
6. Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients.
Gustavsen MT; Midtvedt K; Robertsen I; Woillard JB; Debord J; Klaasen RA; Vethe NT; Bergan S; Åsberg A
Clin Transl Sci; 2020 Nov; 13(6):1327-1335. PubMed ID: 32652886
[TBL] [Abstract][Full Text] [Related]
7. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
[TBL] [Abstract][Full Text] [Related]
8. Dose-Response Relationship Between Diltiazem and Tacrolimus and Its Safety in Renal Transplant Recipients.
Choong CL; Wong HS; Lee FY; Lee CK; Kho JV; Lai YX; Vikneswaran T
Transplant Proc; 2018 Oct; 50(8):2515-2520. PubMed ID: 30316389
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
[TBL] [Abstract][Full Text] [Related]
10. Diltiazem increases tacrolimus concentrations.
Hebert MF; Lam AY
Ann Pharmacother; 1999 Jun; 33(6):680-2. PubMed ID: 10410178
[TBL] [Abstract][Full Text] [Related]
11. Diltiazem use in tacrolimus-treated renal transplant recipients.
Kothari J; Nash M; Zaltzman J; Ramesh Prasad GV
J Clin Pharm Ther; 2004 Oct; 29(5):425-30. PubMed ID: 15482385
[TBL] [Abstract][Full Text] [Related]
12. Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients.
Min DI; Chen HY; Lee MK; Ashton K; Martin MF
Pharmacotherapy; 1997; 17(3):457-63. PubMed ID: 9165550
[TBL] [Abstract][Full Text] [Related]
13. Gender-dependent predictable pharmacokinetic method for tacrolimus exposure monitoring in kidney transplant patients.
Velickovic-Radovanovic R; Mikov M; Catic-Djordjevic A; Stefanovic N; Mitic B; Paunovic G; Cvetkovic T
Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):95-102. PubMed ID: 24596067
[TBL] [Abstract][Full Text] [Related]
14. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
Kuypers DR; Vanrenterghem Y
Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of tacrolimus after the first oral administration in renal transplant recipients on triple immunosuppressive therapy.
Velickovic-Radovanovic RM; Paunovic G; Mikov M; Djordjevic V; Stojanovic M; Catic-Djordjevic A; Cvetkovic T
Basic Clin Pharmacol Toxicol; 2010 Jun; 106(6):505-10. PubMed ID: 20102364
[TBL] [Abstract][Full Text] [Related]
16. Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients.
Zhou LY; Zuo XC; Chen K; Wang JL; Chen QJ; Zhou YN; Yuan H; Ma Y; Zhu LJ; Peng YX; Ming YZ
J Clin Pharm Ther; 2016 Jun; 41(3):341-7. PubMed ID: 27149910
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the pharmacokinetics of tacrolimus and microemulsified cyclosporin in paediatric renal transplant recipients.
Renton KW; Crocker JF; McLellan H; Acott PD
Eur J Clin Pharmacol; 2004 Aug; 60(6):421-6. PubMed ID: 15232662
[TBL] [Abstract][Full Text] [Related]
18. Gender differences in pharmacokinetics of tacrolimus and their clinical significance in kidney transplant recipients.
Velicković-Radovanović R; Mikov M; Paunović G; Djordjević V; Stojanović M; Cvetković T; Djordjević AC
Gend Med; 2011 Feb; 8(1):23-31. PubMed ID: 21497769
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporin C(2) and C(0) concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors.
Ray JE; Keogh AM; McLachlan AJ; Akhlaghi F
J Heart Lung Transplant; 2003 Jul; 22(7):715-22. PubMed ID: 12873538
[TBL] [Abstract][Full Text] [Related]
20. No Apparent Influence of Nonadherence on Tacrolimus Intrapatient Variability in Stable Kidney Transplant Recipients.
Gokoel SRM; Zwart TC; Moes DJAR; van der Boog PJM; de Fijter JW
Ther Drug Monit; 2020 Oct; 42(5):702-709. PubMed ID: 32941396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
